Novateor Resear. (542771)

Score breakdown: P/E: 0/3 · ROCE: 0/2 · Growth: 0/2 · Dividend: 0/1

Key Financials

Strengths

• Sales growth of 212.66% indicates strong recent revenue momentum from a small base.
• Latest quarter sales of ₹2 Cr show some market acceptance for its personal care products.
• Stock trading near its 52-week high of ₹49.19 reflects current investor optimism.
• Personal care is a consumer daily-use category with potential for repeat purchases.
• Small market cap of ₹23 Cr offers large upside if execution and profitability improve.

Concerns

• P/E of 629.67 is an extreme valuation with almost no earnings support.
• Profit growth of -166.67% and latest quarter net profit of ₹-0 Cr show the company is not generating meaningful profits.
• ROCE of 1.69% is below acceptable threshold for a quality business; capital returns are weak.
• Critical data missing: book value, ROE, debt/equity, promoter holding; Piotroski F-Score of 4/9 also signals weak financial health.

AI Analysis

Even in a consumer industry like personal care, a great business must still earn a decent return on capital. Novateor Resear reported a 212.66% jump in sales, but that is meaningless if it cannot convert sales into profits. The latest quarter shows sales of just ₹2 Cr and net profit of ₹-0 Cr; profit growth is -166.67%. A P/E of 629.67 means the market is paying an extraordinary price for a tiny sliver of earnings. Graham would ask: where is the margin of safety? I do not see one. ROCE is only 1.69%, far below what a conservative investor can earn from a simple fixed deposit. The Piotroski F-Score of 4 out of 9 is another warning. Worse, I am flying blind: book value, ROE, promoter holding, and debt/equity are all absent. How can I judge management quality or balance sheet risk without those numbers? The 52-week range of ₹20.08 to ₹49.19 shows the stock has had a fantastic run, but price sentiment is not intrinsic value. At ₹47.50 and a market cap of ₹23 Cr, this is a microcap story stock, not a proven compounder. Buffett would say it is better to be certain about small profits than to hope for large imaginary ones. This company may grow someday, but today it has no durable moat, no dividend, negligible earnings, and enormous valuation risk. A loss-making, near-zero profit business at 629 times earnings is a lottery ticket. In investing, you do not need to act on every ticket. I would pass unless the company proves it can generate real cash earnings over several years. Patience is the smarter trade.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer